A national leader in incision-free surgery performed through natural orifices, the Center for Scarless Surgery at NewYork-Presbyterian Hospital/Columbia University Medical Center is now offering patients with severe, chronic acid reflux disease a unique incision-free procedure called TIF, or transoral incisionless fundoplication.

More than 20 million Americans suffer from gastroesophageal reflux disease (GERD), experienced by many as chronic heartburn. Medication offers short-term relief for some sufferers of this disease. For those seeking a non-prescription alternative, a magnetic device, currently being evaluated at UC San Diego Medical Center, may provide a long-term solution.

Recent reports have indicated that recurrent chest pain is often a result of esophageal motility disorders or gastroesophageal reflux diseases (GERD), which is known as esophageal chest pain. However, very few studies have been performed about esophageal manometric studies, 24-h intra-esophageal pH monitoring and a Holter electrocardiography for the differential diagnosis of chest pain caused by esophageal dysfunctional and/or myocardial ischemia. A research team led by Prof.

Respiratory Technology Corporation (dba Restech) announced that its revolutionary Dx-pH Measurement System has received CE mark approval, allowing introduction to the European Union and all countries recognizing the CE Mark. This approval from the European Union certifies Restech has met EU health, safety and environmental requirements that ensure consumer safety.

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved KAPIDEX? (dexlansoprazole) delayed release capsules for the once-daily, oral treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE.